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DBPCFC- Double-blind, placebo-controlled food challengeED- Eliciting dose
ED01- Amount of allergen expected to cause objective
symptoms in 1% of the population with that allergy
ED05- Amount of allergen expected to cause objective
symptoms in 5% of the population with that allergy
EIA- Exercise-induced anaphylaxis
FAO- Food and Agriculture Organization
FC- Food challenge
PAL- Precautionary allergen labelingPFAS- Pollen food allergy syndrome
WHO-World Health Organizationindividuals, but a similar level of evidence is lacking for other
priority allergens. We present the results of a rapid evidence
assessment and meta-analysis for the risk of anaphylaxis to a
low-level allergen exposure for priority allergens. On the
basis of this analysis, we propose that peanut can and should
be considered an exemplar allergen for the hazard charac-
terization at a low-level allergen exposure.  2021 The
Authors. Published by Elsevier Inc. on behalf of the American
Academy of Allergy, Asthma & Immunology. This is an open
access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/). (J Allergy Clin
Immunol Pract 2021;-:---)
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reaction in 5% of the at-risk allergic population.6 Such data can
and have been used to inform the need for PAL, albeit on a
voluntary basis.4,5 However, until now, the main consideration
has been the proportion of allergic individuals who will have
objective symptoms at these levels of exposure, and not neces-
sarily a consideration of how “severe” such symptoms may be.
Thus, there is also a need to better characterize the hazard8,9 at a
given dose—the relationship between a level of allergen exposure
(dose) and the nature/severity of any subsequent adverse health
outcome—because this relationship is perceived to be of critical
importance by allergic consumers and remains the focus of
clinical, scientific, and regulatory debate.
Under current European legislation, food may be considered
“unsafe” if injurious to health, for example, due to the “particular
health sensitivities of a specific category of consumers” such as
those with food allergies. However, what constitutes “injurious to
health” is not precisely defined; indeed, interpretation of the law
indicates that provided a food product is labeled in accordance
with legal requirements (ie, including priority allergens where
appropriate), food is safe, unless it is specifically marketed for
people with those health sensitivities.10 In Canada, food is also
considered to be unsafe if it contains undeclared food allergens,
whether as an ingredient or unintended presence due to shared
production facilities11; however, the requirement for allergen
declaration “does not apply to a food allergen or gluten that is
present in a prepackaged product as a result of cross-contami-
nation.”12 The Food Allergen Labeling and Consumer Protec-
tion Act (2004) in the USA more explicitly enshrines the concept
of an “allergic response that causes a risk to human health,”
which implies that some reactions might not pose such a risk.13
By definition, therefore, there is a hierarchy of risks faced by
people with food allergy, some of which might not be considered
to be a risk to human health.14 Fatal food anaphylaxis is the most
extreme harm that can occur, but fortunately, it is a very rare
event, occurring at less than 1 per 100,000 person-years in food-
allergic individuals (Figure 1).15 Investigating fatal reactions is
extremely difficult, as it is usually impossible to determine the
amount of allergen that has been consumed or the presence of
other factors that might have contributed to the fatal outcome
(although to date, there are no reports of fatal reactions to levels
of exposure not exceeding the ED05 for any allergenic food).
20
Although fatal reactions can theoretically occur to any allergen,
the vast majority of fatal reactions reported in the literature are
due to peanut, tree nuts, seafood, and cow’s milk.21 Further-
more, such severe reactions are usually due to the consumption
of nonprepacked foods (foods from restaurants, bakeries, take-
away or fast-food outlets, etc.)20,22; these foods are unlikely to
have had a PAL statement in the same way as is the case with
prepacked foods. The rarity of fatal reactions and their limited
relevance in the context of managing unintended allergen pres-
ence makes fatal reactions an inappropriate basis for character-
izing the hazard posed by such presence. Furthermore, allergic
consumers want more than “just” protection from fatal reactions,
given that moderate allergic reactions can be very unpleasant,
even if not themselves life-threatening.
If fatal reactions are not appropriate as an outcome for hazard
characterization, arguably it is more important to protect the
consumer from severe reactions at a population level. However,
the assignment of severity for food-induced allergic reactions is
inconsistent in the literature, and each method has itslimitations.23,24 There is no universally accepted system for
scoring the severity of food-allergic reactions. However, most
food-allergic consumers and clinicians would consider reactions
involving airway/breathing and/or cardiovascular compromise as
severe, and there is an international consensus that such symp-
toms constitute “anaphylaxis” (despite there being multiple
definitions for anaphylaxis in the literature).24 Notwithstanding,
even nonfatal anaphylaxis is not a single entity in terms of
severity (Figure 1). Published data indicate that at least 80% of
anaphylaxis reactions are not treated with epinephrine/adrenaline
(contrary to international guidelines), but resolve spontane-
ously.16,17 Although nontreatment must not to be condoned, it
does demonstrate the spectrum of severity for anaphylaxis, from
mild reactions that spontaneously resolve to more severe re-
actions refractory to initial treatment (occurring in 3.4% [95%
confidence interval (CI): 1.9%-5.9%] of treated reactions).18
If reference doses (such as ED05) are to be used to inform the
need for PAL or other risk management options, then it is essential
to characterize the hazard associated with these low-level expo-
sures. Assessing the risk of anaphylaxis to a low-dose allergen
exposure would therefore seem to be appropriate in terms of this
hazard characterization. For example, after an exposure to an ED05
amount of peanut (an amount which would, by definition, not
cause an objective allergic reaction in 95% of peanut-allergic in-
dividuals), one would expect 2.3 episodes of anaphylaxis per 1000
exposures in the peanut-allergic population.19 At least 80% of
these are mild reactions (which, in reality, resolve spontaneously
when allergic individuals choose not to follow medical advice and
treat), whereas 97% of the remainder would respond to first-line
treatment (with epinephrine/adrenaline).18 In those reporting
anaphylaxis to any level of exposure for a food allergen, the risk of
fatal outcome is estimated to be <1:10,00015; it is likely that this
rate would be even lower after an ED05 level of exposure.
Therefore, the expected rate of fatal reaction to an ED05 exposure
in an allergic individual can be estimated to be <1 per million
(Figure 1). There are currently no reports in the literature of fatal
reactions to this level of exposure, for any allergenic food.
For peanut, there are now published data relating to over 3000
double-blind, placebo-controlled challenges in allergic in-
dividuals to inform a reference dose and characterize the hazard
associated with an ED05 exposure.
19 However, for other priority
allergens currently defined by the Food and Agriculture Orga-
nization/World Health Organization (FAO/WHO) Codex Ali-
mentarius (cereals containing gluten; crustacea, egg, fish,
soybean, milk, tree nuts), this level of evidence (both quantity
and quality; eg, from double-blind challenges) is lacking, which
results in more uncertainty in the estimate of the rate of
anaphylaxis to low-level allergen exposures to these allergens. If
peanut can be considered a “worst-case” allergen in terms of
hazard and risk characterization at low levels of exposure, then
this would greatly facilitate attempts to define reference doses
and introduce a consistent regulatory framework for the use of
PAL acceptable at an international level.
In this rostrum, we propose that “anaphylaxis” can be used as a
“marker” for hazard characterization, that is, severity. We present
the results of a rapid evidence assessment25 and meta-analysis
evaluating the proportion of reactions to a low-dose allergen
exposure that result in anaphylaxis for other priority allergens (see
this article’s Online Repository at www.jaci-inpractice.org for
methodology), to assess the evidence base and evaluate the un-
certainty in the evidence (by comparing the 95% CIs for the rate
TABLE I. Proportion of peanut-allergic individuals who would be expected to have symptoms after an exposure to an ED01 or ED05
amount of peanut
Peanut
1 mg of protein
(zupper 95% CI for
cumulative ED01)
2.1 mg of protein
([discrete ED05)
7.1 mg of protein
([upper 95% CI for
cumulative ED05)
Any symptom (subjective or objective) 14%27 to 23%28 20%27 to 35%28 35%27 to 45%28
Subjective symptoms 13%27 to 22%28 15% to 30%26-28 27%27 to 37%28
OAS only 5% to 10%28 5% to 10%28 5% to 10%28
Any objective symptom 1% 5% 8%6
Anaphylaxis rate:
 In those reacting to this dose with objective symptoms 4.2%19 (95% CI: 0.7%-22.3%) 4.5%19 (95% CI: 1.9%-10.1%)
 Overall, in the peanut-allergic population 0.04%19 (95% CI: 0.01%-0.22%) 0.23%19 (95% CI: 0.1%-0.5%)
CI, Confidence interval; ED01, amount of allergen expected to cause objective symptoms in 1% of the population with that allergy; ED05, amount of allergen expected to cause
objective symptoms in 5% of the population with that allergy; OAS, oral allergy symptoms.
The cumulative ED01 and ED05 for peanut is 0.7 (95% CI: 0.5-1.3) mg of protein and 3.9 (95% CI: 2.8-7.1) mg of protein, respectively; the discrete ED05 is 2.1 (95% CI: 1.2-
4.6) mg of protein.6 Estimates of the occurrence of different symptoms are based on the literature.26-28
FIGURE 1. Hierarchy of risks faced by people susceptible to IgE-mediated food allergy. Estimates refer to occurrence of allergic symptoms
at ED05 levels of exposure in food-allergic individuals.
15-19 ED05, Amount of allergen expected to cause objective symptoms in 5% of the
population with that allergy.
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4 TURNER ETALof anaphylaxis at low-level exposures for peanut and other priority
allergens). We conclude that despite the lower level of evidence—
both quantity and quality (eg, not just from a double-blind, pla-
cebo-controlled food challenge [DBPCFC])—for allergens other
than peanut, there are no data to suggest that other priority al-
lergens cause “more severe” reactions at an ED05 level of exposure.
On this basis, we therefore propose that peanut can and should be
considered an exemplar allergen for hazard characterization at a
low-level allergen exposure.PEANUT
Patel et al19 recently published a systematic review of over
3000 DBPCFCs to peanut. This analysis found that approxi-
mately 4.5% (95% CI: 1.9%-10.1%) of individuals who reacted
to 5 mg of peanut protein and 4.2% (95% CI: 0.7%-22.3%)
of individuals who reacted to 1 mg with objective symptoms
experienced anaphylaxis (exposures that approximate to the up-
per limit of the 95% CI for the amount of allergen expected tocause objective symptoms in 1% of the population with that
allergy [ED01] and ED05 for peanut, respectively).
6 A further 3
reports were identified with respect to subjective symptoms
experienced after a low-dose peanut exposure at food challenge
(FC). In the Peanut Allergen Threshold Study, 378 unselected
peanut-allergic children underwent an open, single-dose chal-
lenge to 1.5 mg of peanut protein; 67 (17.7%; 95% CI: 14%-
22%) developed subjective symptoms.26 Two further series
provide dose-distribution curves for any (subjective þ objective)
symptoms at a DBPCFC to peanut.27,28 The latter also reported
that at cumulative doses of 0.33 to 3.33 mg of peanut protein,
around 5% to 10% of peanut-allergic individuals will experience
mild transient oral allergy symptoms.28 At an ED05 exposure,
around one-third of peanut-allergic individuals experience sub-
jective symptoms (the vast majority of a mild and transient na-
ture); 5% will have objective symptoms (equivalent to 50
peanut-allergic individuals per 1000), and only 4.5% of those
(equivalent to 2.3 per 1000) are predicted to develop anaphylaxis
(Table I and Figure 2).
FIGURE 2. Proportion of peanut-allergic individuals expected to have subjective or objective symptoms after an exposure to an ED05 or
ED01 amount of peanut. Data from Table I. CI, Confidence interval; ED01, amount of allergen expected to cause objective symptoms in 1%
of the population with that allergy; ED05, amount of allergen expected to cause objective symptoms in 5% of the population with that
allergy; OAS, oral allergy symptoms.





to £30 mg of protein
Anaphylaxis to
£30 mg of protein Symptoms
Almond 6/69 (9%) 0/6
Brazil 7/100 (7%) 0/7
Cashew 36/83 (43%) 10/36 0/10
Hazelnut 30/70 (43%) 6/30 0/6
Macadamia 16/100 (16%) 3/16 1/3 Laryngeal þ lower respiratory symptoms
Pecan 26/92 (28%) 5/26 0/5
Pistachio 34/94 (36%) 4/34 0/4
Walnut 36/81 (44%) 7/36 1/7 Pruritic rash, local angioedema, stridor
Peanut 37/66 (56%) 8/37 0/8
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Three studies were identified in which nut-allergic patients
underwent a formal FC to a range of tree nuts. In the Pronutsstudy, a multicenter European study, 122 children (median age,
5.5 years) underwent multiple open FCs to peanut, tree nut, or
sesame to assess coexistent allergy.29 A total of 689 FCs to tree
TABLE III. Proportion of positive food challenges (to any dose)








Almond 30/44 (68%) 0% 0% 0%
Cashew 151/312 (48%) 1.3% 6.0% 0.7%
Hazelnut 68/95 (72%) 0% 2.9% 0%
Pecan 88/165 (53%) 2.3% 9.1% 0%
Pistachio 60/93 (65%) 1.7% 3.3% 0%
Walnut 121/195 (62%) 0% 2.5% 0%
Peanut 347/795 (44%) 1.2% 8.1% 0.3%
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6 TURNER ETALnuts were performed, of which 191 (28%) were positive. Of 35
individuals who reacted to the first challenge dose (30 mg of
protein), only 2 (5.7%) had anaphylaxis (Table II). Purington
et al30 undertook a retrospective analysis of 410 individuals
(median, 9 years; range, 1-52 years) who underwent DBPCFCs
at 7 sites in the USA, which included 512 positive challenges to
tree nuts. Severe symptoms were seen at all dosing levels, with no
evidence to suggest that rates of anaphylaxis were greater for tree
nuts at any level of exposure compared with peanut (Table III).
After peanut, cashew and pecan were associated with the highest
rates of anaphylaxis.
Further data relating to pecan and cashew can be found in the
NutCracker study.31 In this study, 83 patients (median age, 8.7
years; range, 3-24 years) were prospectively evaluated for allergy
to walnut, pecan, cashew, pistachio, hazelnut, and almond.31
Although patients did not undergo a challenge to peanut, rates
of lower respiratory symptoms and/or the need for rescue
epinephrine due to reactions across the entire FC dosing range
were not greater than those reported in the literature for peanut.
Finally, we assessed the rate of anaphylaxis to very low
(upper 95th CI for the ED05)6 levels of allergen consumption
at FC to cashew27,29-36 (Table E1, available in this article’s
Online Repository at www.jaci-inpractice.org), hazelnut27-31,37-40
(Table E2, available in this article’s Online Repository at www.
jaci-inpractice.org), and walnut29,30,41-43 (Table E3, available
in this article’s Online Repository at www.jaci-inpractice.org)
reported in the literature, and undertook a meta-analysis
(Figures E1-E3, available in this article’s Online Repository at
www.jaci-inpractice.org). These data are summarized in
Table IV. Hazelnut was associated with a higher rate of subjec-
tive symptoms at lower doses compared with peanut—something
not unexpected, because it is commonly implicated as a cause of
pollen food allergy syndrome (PFAS) due to Bet v 1 cross-
reactivity with birch pollen.39 This is also consistent with data
published by Masthoff et al38 that after a low-dose exposure to
hazelnut (10 mg of protein), subjective symptoms are almost
twice as common in adults (in whom PFAS is more common)
than in children. Overall, we found no evidence to suggest that
tree nut-allergic individuals are more likely to experience
anaphylaxis to low levels of exposure to a tree nut, compared
with peanut.
SESAME
Sesame is already a priority allergen in the European Union,
Canada, Australia, and New Zealand; the FASTER Act was
recently passed in the USA, adding sesame to the list of priorityallergens that must be declared when present as an ingredient in
foods. Nine published studies were identified for sesame FCs
(Table E4, available in this article’s Online Repository at www.
jaci-inpractice.org), representing 271 positive FCs.29,30,44-50
Although some objective reactions were reported to low levels of
exposure, only 2 (0.7%) anaphylaxis reactions were reported to
<60 mg level exposures (equivalent to upper 95% CI for ED05 for
sesame).6 At meta-analysis, this rate was equivalent to that for
peanut, with a rate of anaphylaxis to ED05 levels of exposure of
3.0% (95% CI: 0.8%-11%) for sesame (Figure E4, available in
this article’s Online Repository at www.jaci-inpractice.org).
COW’S MILK
Seventeen studies were identified representing 1045 positive
FCs (98% in children) (Table E5, available in this article’s
Online Repository at www.jaci-inpractice.org).27,30,51-65 At
meta-analysis, the estimated rate of anaphylaxis in those in-
dividuals reacting with objective symptoms to ED05 levels of
exposure was 4.9% (95% CI: 2.1%-11%) (Figure E5, available
in this article’s Online Repository at www.jaci-inpractice.org).
Two studies also reported the occurrence of subjective symptoms
to low-level exposures. Blom et al27 estimated that 13% to 20%
of individuals with an allergy to cow’s milk will develop sub-
jective symptoms to ED05 exposures (2.4-6.6 mg of cow’s milk
protein). Turner et al51 reported a single-dose challenge study in
which 50 of 172 milk-allergic individuals (29%) developed any
symptoms to 0.5 mg of cow’s milk protein; at least 19%
developed transient subjective symptoms, consistent with the
estimate of Blom et al.
Although cow’s milk allergy is one of the most common food
allergies in early childhood, the majority of children tend to
outgrow it. This may explain why there is a perception that cow’s
milk allergy is less “serious” than other food allergies.66,67 In
reality, there are different phenotypes and children with per-
sisting cow’s milk allergy may be more at risk of severe reactions:
indeed, cow’s milk is the single most common cause of fatal
anaphylaxis in children in the United Kingdom68 and a common
cause of fatal and near-fatal reactions elsewhere.21
HEN’S EGG
Twenty studies were identified (Table E6, available in this
article’s Online Repository at www.jaci-inpractice.org), repre-
senting 1180 positive FCs, the vast majority of which (at least
95%) were in children.27,30,48,53,58,62,63,69-82 At meta-analysis,
the estimated rate of anaphylaxis in those individuals reacting
with objective symptoms to ED05 levels of exposure was 1.5%
(95% CI: 0.02%-55%) (Figure E6, available in this article’s
Online Repository at www.jaci-inpractice.org). One study (Blom
et al27) also provided an estimate of the occurrence of any
symptoms to ED05 levels of exposure of 9% to 14% (which
includes both subjective and objective symptoms). Data suggest
that egg tends to cause less anaphylaxis (lower respiratory
symptoms) and more gastrointestinal symptoms compared with
other allergens.83 There are only 2 fatalities to egg reported in the
literature,21,68,84 despite egg being one of the most common food
allergens in preschool children.
WHEAT
IgE-mediated wheat allergy is a relatively uncommon food al-
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TURNER ETAL 7adults21; celiac disease and noneIgE-mediated wheat allergy are
more common. However, near-fatal and fatal anaphylaxis have
been reported.21,85,86 Furthermore, wheat anaphylaxis may be
more associated with anaphylactic shock (involving cardiovascular
compromise) than other food allergens.85 Ten studies were iden-
tified, representing 348 positive FCs (at least 90% in children)
(Table E7, available in this article’s Online Repository at www.
jaci-inpractice.org).30,53,58,86-92 At meta-analysis, the rate of
anaphylaxis in those individuals reacting with objective symptoms
to ED05 levels of exposure was estimated to be 2.2% (95% CI:
0.02%-75%) (Figure E7, available in this article’s Online Re-
pository at www.jaci-inpractice.org). Wheat is also the most
common food allergen implicated in food-dependent, exercise-
induced anaphylaxis (EIA).85 The available literature suggests that
exposure levels causing wheat-dependent EIA in the presence of a
relevant cofactor are typically in excess of those triggering reactions
in conventional IgE-mediated wheat allergy.93,94
FISH AND SHELLFISH
Threshold data relating to fish and shellfish are limited, in part
because of the multiple different species of seafood globally and
limited published threshold data across these foods. Moreover,
fish and shellfish are reported to have much higher reaction
thresholds compared with other food allergens. Despite this,
seafood is an emerging and important cause of anaphylaxis,
including near-fatal and fatal anaphylaxis globally.21 Data from
EuroPrevall indicate that around one-third of individuals allergic
to seafood would experience subjective symptoms to an ED05
level of exposure of cod or prawn/shrimp.28 We identified 6
studies in the literature, 3 with respect to finned fish (typically
cod)28,95,96 (Table E8, available in this article’s Online Re-
pository at www.jaci-inpractice.org) and 3 evaluating thresholds
to prawn/shrimp (Table E9, available in this article’s Online
Repository at www.jaci-inpractice.org).28,97,98 With the paucity
of data, no meta-analysis could be performed. The lack of data
also results in wide estimated CIs for estimated ED05. Although
anaphylaxis has been reported to ED05 levels of exposure, there is
no evidence that this occurs more frequently than with peanut;
however, the underlying evidence base is far more limited for this
food group.
SOYBEAN
The inclusion of soya as a priority allergen in Codex is under
review, with a recent recommendation from an FAO/WHO
Expert Committee for its removal as a global priority allergen on
the basis of a low level of prevalence and low frequency as a cause
of anaphylaxis.99 For soybean, 5 studies were identified in the
literature (Table E10, available in this article’s Online Repository
at www.jaci-inpractice.org).27,58,100-102 Consistent with data
suggesting that soybean is an uncommon cause of anaphylaxis
globally,21 no cases of anaphylaxis to low (<200 mg of protein)
levels of exposure were identified.
REPRODUCIBILITY OF THRESHOLDS AND
LIKELIHOOD OF ANAPHYLAXIS
Patel et al19 analyzed data from 534 individuals who under-
went at least 2 peanut-DBPCFCs over time, to assess the
reproducibility of thresholds and recurrence of anaphylaxis in
peanut-allergic individuals. Although the intraindividual vari-
ability in ED varied by up to 3-log, in the majority 71.2% (95%
FIGURE 3. Factors that can modulate severity of allergic reactions. Reprinted with permission from Dubois et al.14 ACE, Angiotensin
converting enzyme; BHR, bronchial hyperresponsiveness; EMS, emergency medical services; NSAID, nonsteroidal anti-inflammatory
drug; OIT, oral immunotherapy.
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change—equivalent to a single dosing interval when using a
PRACTALL-style semilogarithmic dosing regimen.103 There was
a similar degree of variability in the reproducibility of the dose at
which participants experienced anaphylaxis; reassuringly,
although some peanut-allergic individuals tolerated an ED05
exposure on one occasion but then reacted on another, no such
subject developed anaphylaxis in this cohort. There are very
limited data on the reproducibility of clinical thresholds for al-
lergens other than peanut. Limited data (n z 20) have been
published for egg69 and wheat,87 with no evidence of increased
variability in threshold compared with peanut (although for egg,
the study was in children exposed to “baked” egg on a regular
basis).
Multiple factors can impact on the severity of food-induced
allergic reactions, as outlined in Figure 3. These include co-
factors or “augmentation” factors such as exercise, stress, medi-
cation, sleep deprivation, and alcohol that appear to alter both
the threshold at which individuals experience symptoms and the
severity of symptoms at any given level of exposure.14,104
Importantly, these cofactors are not universal and inconsis-
tently experienced by individuals; in many, if not most in-
dividuals, the most well-described factors (exercise,
menstruation, alcohol) seem not to impact significantly on re-
action severity.104 In a retrospective survey of almost 500 adults
with food allergy, only a small proportion used medication that
could influence severity, and under 10% reported exercise or
alcohol as a relevant factor in reactions due to inadvertentexposure.105 The same study group recently published a pro-
spective evaluation of accidental reactions in 157 patients over a
1-year period. Although 74% of reactions had at least 1 potential
cofactor, there was no relationship between the presence of a
cofactor and reaction severity.106
The TRACE peanut study evaluated the impact of significant
exercise and sleep deprivation on peanut-induced allergic re-
actions in 100 peanut-allergic adults, using a randomized study
design.107 On the basis of statistical modeling (rather than raw
data), the authors reported a significant impact of both cofactors
on reducing clinical thresholds by 45%. However, this
decrease—around a 1/2-log, equivalent to a single dosing interval
when using a PRACTALL-style semilogarithmic dosing
regimen—is well within the intraindividual variation in reaction
threshold reported by Patel et al.19 Indeed, in the TRACE study,
the factor with the largest impact in threshold variability was the
clinical center at which participants were evaluated. Furthermore,
exercise was only identified as a significant factor in 1 of the 2
clinical centers.107,108 To date, no data relating to reaction
severity from the TRACE study have been published. Therefore,
although there can be an impact of cofactors on thresholds and
severity in some individuals, this does not appear to be any
greater than the inherent shift in both clinical thresholds and risk
of anaphylaxis identified in the wider food-allergic population,
nor does it appear that such effects are predictable. Consumers
with food-dependent EIA (predominantly to wheat and possibly
seafood) may be an exception: such individuals appear to be
tolerant to the allergen in the absence of the relevant cofactor.
TABLE V. Summary table for the rate of anaphylaxis to ED05 levels of exposure in allergic individuals
Allergen
Evidence base






the 95% CI for
cumulative ED05
(mg protein)
Expected rate of symptoms
to a level of allergen exposure




allergen exposure £ upper
95% CI for the cumulative ED05,









allergic to this food
Peanut 3151 DBPCFCs 2.1 [1.2-4.6] 7.1 35-45 8 4.5% (95% CI: 1.9%-10%) 2.3 per 1000 (95% CI: 1.0-5.1 per 1000)
Cashew 323 DBPCFCs
421 open FCs
0.8 [0.2-5.0] 9.4 32 12 4.9% (95% CI: 2.2%-10.5%) 2.5 per 1000 (95% CI: 1.1-5.3 per 1000)
Hazelnut 391 DBPCFCs
43 open FCs
3.5 [1.3-12.1] 15.7 approx. 75 9 2.5% (95% CI: 0.3%-15.8%) 1.2 per 1000 (95% CI: 0.2-7.9 per 1000)
Walnut 194 DBPCFCs
156 open FCs
0.8 [0.1-8.9] 13.0 approx. 60 14 5.3% (95% CI: 2.0%-13%) 2.7 per 1000 (95% CI: 1.0-6.7 per 1000)
Sesame 59 DBPCFCs
214 open FCs
2.7 [0.4-34] 58 Not reported 20 3.0% (95% CI: 0.8%-11%) 1.5 per 1000 (95% CI: 0.4-5.7 per 1000)
Cow’s Milk 728 DBPCFCs
317 other FCs
2.4 [1.3-5.0] 6.6 20 9 4.9% (95% CI: 2.1%-11%) 2.5 per 1000 (95% CI: 1.1-5.5 per 1000)
Egg 637 DBPCFCs
543 other FCs
2.3 [1.2-4.7] 5.3 14 9 1.5% (95% CI: 0.02%-55%) 0.8 per 1000 (95% CI: 0-27 per 1000)
Wheat 123 DBPCFCs
23 open FCs
6.1 [2.6-15.6] 25 Not reported 11 2.2% (95% CI: 0.02%-75%) 1.1 per 1000 (95% CI: 0-38 per 1000)
Fish 59 DBPCFCs 12.1 [4.5-44] 102 58 25 Insufficient data for meta-analysis
Shrimp 12 DBPCFCs
46 open FCs
280 [69-880] 1850 57 19 Insufficient data for meta-analysis
Soya 89 DBPCFCs
51 open FCs
10.0 [2.2-55] 76 Not reported Not reported 0% (95% CI: 0%-16.8%) 0 per 1000 (95% CI: 0-8.4 per 1000)
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10 TURNER ETALHowever, at least for wheat-dependent EIA, EDs for clinical
reaction are typically 2 to 3 log greater than ED05 levels of
exposure.93,94
SUMMARY AND CONCLUSIONS
There is a consensus that “zero risk” is not realistic or
achievable with respect to food allergen risk management.109 An
evidence-based approach to the use of PAL should improve both
allergen risk communication to food-allergic consumers and their
understanding and application of this information (different
outcomes, but of equal importance). However, the reference
doses used to inform the use of PAL must be guided by the
residual “tolerable risk” and supported by current methods of
allergen detection and risk management.
In this rapid evidence assessment and meta-analysis, we found
no evidence to suggest that other priority allergens can result in a
higher rate of anaphylaxis at low doses of allergen exposure (at
around ED05 levels of exposure, which would be expected to
cause objective symptoms in 5% of individuals allergic to that
specific allergen), compared with peanut (Table V). Further-
more, we did not identify any cases of anaphylaxis at ED05
levels that were refractory to treatment (where administered).
Indeed, for many of the reports included in this analysis, a sig-
nificant proportion of anaphylaxis reactions were not treated with
epinephrine/adrenaline (reflecting both local variations in inter-
pretation of anaphylaxis criteria and management of reactions by
clinicians). At these low levels of exposure, the probability of
anaphylaxis would be expected to be 0.25%. At least 80% of
these episodes would resolve without treatment, whereas >97%
of the remainder would respond to first-line treatment (with
epinephrine/adrenaline). The risk of a fatal reaction to an ED05
exposure is estimated to be <1 per million; to date, there are no
reports in the literature of fatal reactions to this level of exposure,
for any allergenic food.
These data further support the use of ED to inform the need
for PAL. Given that the evidence base is strongest for peanut,
with data encompassing over 3000 DBPCFCs reported in the
literature (including evidence relating to reproducibility of reac-
tion thresholds and the impact of cofactors), we propose that
peanut can be used as an exemplar allergen in terms of hazard
characterization at ED05 levels of exposure or below. Further
work is underway at a global level to consider how reference
doses might be used to inform allergen risk management,110 and
importantly, how this can be communicated in a reassuring way
to consumers with food allergy. Whether the nature of symptoms
that are experienced at an ED05 level of exposure are acceptable
to stakeholders, including food-allergic consumers, and could be
considered to be a “tolerable risk” requires further consensus.
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